News Medical

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of its Supplemental Biologics ...
Nasdaq

Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids

Allergan plc AGN announced that the FDA has approved its supplemental biologics license application (sBLA) to expand the label of its blockbuster product Botox for pediatric patients with upper limb ...
Business Insider

FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity

DUBLIN, March 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license applications ...
Business Insider

FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity

NORTH CHICAGO, Ill., July 9, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License ...
FierceBiotech

Allergan Inc. (AGN)'s BOTOX(R) (OnabotulinumtoxinA) Receives FDA Approval for Treatment of Upper Limb Spasticity in Adults

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN - News) today announced that the United States Food and Drug Administration (FDA) has approved BOTOX® (onabotulinumtoxinA) for the treatment ...